

OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC - (In Administration) (June 2025)

The Intellectual Property of a Biopharmaceutical Company.

Summary

- OTH operated as a biopharmaceutical company focused on developing new medicines targeting the endocannabinoid system. The Company's primary assets include a proprietary and licensed intellectual property (IP) portfolio and clinical-stage drug development programmes.
- Website - www.oxcantech.com

Intellectual Property Portfolio

- OTH's IP portfolio forms the foundation of its drug development strategy. The Company holds:
 - (a) A worldwide exclusive licence (excluding Japan) for a new chemical entity (NCE) from AskAt Inc.
 - (b) "Proprietarily Designed Inhaler", designed for OCT's specific 2nd program.
 - (c) Exclusive rights to 336 cannabinoid derivatives, licensed from Canopy Growth Corporation. These are a subset of a larger portfolio of 1,915 compounds covered by 14 patent families.

Drug Development Programmes

- OTH involved in developing multiple cannabinoid-based medicines, with two lead programmes:
 - (a) Programme 1 – OCT461201 (CB2 Agonist for Neuropathic Pain)
 - (i) OCTH's lead clinical-stage programme, OCT461201, being developed to treat neuropathic pain. A Phase 1 (Single Ascending Dose) study has been completed, demonstrating positive safety data and no drug-related adverse effects.

- (ii) The next step is a Multiple Ascending Dose (MAD) + Food Effect study, which is currently in planning. A Phase 2 trial will focus on neuropathic pain conditions, initially targeting Diabetic Peripheral Neuropathy (DPN).
- (b) Programme 2 – OCT130401 (Inhaled Synthetic Phytocannabinoids via pMDI targeting Trigeminal Neuralgia (TN))
 - (i) This has a full pre-clinical data package and is ready to start a Phase 1. The trial was to be conducted in Australia, where the regulatory process is faster than other jurisdictions and which benefits from favourable R&D incentives.



Expressions of Interest

- Interested parties will be required to sign a nondisclosure agreement (NDA) before further information is provided.
- Expressions of interest are required as soon as possible, please note any sale will be via an Administration process and likely to be on an accelerated timescale.

For Further Information

Further information is available upon completion and return of a Non-Disclosure Agreement (NDA), which is available on request. Enquires should be directed in the first instance to:

Name: Stephen Milner FNAVA

E. stephen.milner@eddisons.com

Important Notice

The information above has been supplied by our Client and should not be relied upon as statements or representations of fact or warranties of any kind. Eddisons, its Directors and employees shall not be responsible for any error, omission or misstatement. Neither we nor our Client accept any responsibility whatsoever in respect of these particulars, which are simply offered as a general indication to parties who may be interested. Any notice of sale does not constitute an offer or contract.